📣 VC round data is live. Check it out!
- Public Comps
- DaShenLin Pharmaceutical
DaShenLin Pharmaceutical Valuation Multiples
Discover revenue and EBITDA valuation multiples for DaShenLin Pharmaceutical and similar public comparables like COSMOS Pharmaceutical, Sundrug, Fragua, Sugi Holdings and more.
DaShenLin Pharmaceutical Overview
About DaShenLin Pharmaceutical
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
Founded
1999
HQ

Employees
N/A
Website
Sectors
Financials (LTM)
EV
$3B
Valuation Multiples
Start free trialDaShenLin Pharmaceutical Financials
DaShenLin Pharmaceutical reported last 12-month revenue of $4B and EBITDA of $512M.
In the same LTM period, DaShenLin Pharmaceutical generated $1B in gross profit, $512M in EBITDA, and $193M in net income.
Revenue (LTM)
DaShenLin Pharmaceutical P&L
In the most recent fiscal year, DaShenLin Pharmaceutical reported revenue of $4B and EBITDA of $522M.
DaShenLin Pharmaceutical is profitable as of last fiscal year, with gross margin of 34%, EBITDA margin of 13%, and net margin of 4%.
Financial data powered by Morningstar, Inc.
DaShenLin Pharmaceutical Stock Performance
DaShenLin Pharmaceutical has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
DaShenLin Pharmaceutical's stock price is $2.74.
DaShenLin Pharmaceutical share price increased by 0.1% in the last 30 days, and by 8.5% in the last year.
DaShenLin Pharmaceutical has an EPS (earnings per share) of $0.16.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | 0.1% | -4.5% | 8.5% | $0.16 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDaShenLin Pharmaceutical Valuation Multiples
DaShenLin Pharmaceutical trades at 0.7x EV/Revenue multiple, and 5.5x EV/EBITDA.
EV / Revenue (LTM)
DaShenLin Pharmaceutical Financial Valuation Multiples
As of May 4, 2026, DaShenLin Pharmaceutical has market cap of $3B and EV of $3B.
DaShenLin Pharmaceutical has a P/E ratio of 16.2x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified DaShenLin Pharmaceutical Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


DaShenLin Pharmaceutical Margins & Growth Rates
DaShenLin Pharmaceutical grew revenue by 8% but EBITDA decreased by 5% in the last fiscal year.
In the most recent fiscal year, DaShenLin Pharmaceutical reported gross margin of 34%, EBITDA margin of 13%, and net margin of 4%.
DaShenLin Pharmaceutical Margins
DaShenLin Pharmaceutical Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
DaShenLin Pharmaceutical Operational KPIs
DaShenLin Pharmaceutical's Rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DaShenLin Pharmaceutical's Rule of X is 32% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
DaShenLin Pharmaceutical Competitors
DaShenLin Pharmaceutical competitors include COSMOS Pharmaceutical, Sundrug, Fragua, Sugi Holdings, Nahdi Medical, Ebos Group, Clicks Group, Jointown Pharmaceutical, Kusuri No Aoki and Yifeng Pharmacy.
Most DaShenLin Pharmaceutical public comparables operate across Pharmacies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.5x | 0.5x | 7.7x | 7.7x | |||
| 0.5x | 0.5x | 6.3x | 6.3x | |||
| 0.4x | 0.3x | 7.0x | 4.4x | |||
| 0.6x | 0.5x | 9.7x | 7.9x | |||
| 1.4x | 1.4x | 8.5x | 8.4x | |||
| 0.5x | 0.4x | 10.7x | 8.4x | |||
| 1.3x | 1.2x | 9.3x | 9.0x | |||
| 0.2x | 0.2x | 5.3x | 5.7x | |||
This data is available for Pro users. Sign up to see all DaShenLin Pharmaceutical competitors and their valuation data. Start Free Trial | ||||||
DaShenLin Pharmaceutical Investment Activity
DaShenLin Pharmaceutical has invested in 2 companies to date.
Latest investment by DaShenLin Pharmaceutical was on November 8th 2018. DaShenLin Pharmaceutical invested in LASO Biotech in their $5M Angel round (EV/Revenue multiple of ).
Latest Investments by DaShenLin Pharmaceutical
| Description | LASO Biotech is a Porto, Portugal-headquartered developer and manufacturer of microarray platforms for high-throughput analysis in genomics, proteomics, and diagnostics. The proprietary LASOchip technology prints 100-micron spots on 25x75mm slides, enabling multiplex assays for gene expression, protein profiling, and biomarker discovery. Supporting biomedical research labs and diagnostic firms, LASO integrates with standard scanners and offers custom array design services for applications in cancer and infectious diseases. | One Tree Pharmaceutical is a retail pharmacy chain that distributes prescription medications alongside health products, nursing supplies, and wellness services, shaping trends in consumer healthcare. |
| HQ Country | ||
| HQ City | Beijing | Guiyang |
| Deal Date | 8 Nov 2018 | 1 Apr 2017 |
| Round | Angel | Angel |
| Raised | $5M | $400K |
| Investors | DaShenLin Pharmaceutical | Daohe Touzi; DaShenLin Pharmaceutical; Guizhou Wenhua Chantou; Huatai Zijin Investment; Loyeer Capital; Xinyu Xinde Touzi |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all DaShenLin Pharmaceutical investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout DaShenLin Pharmaceutical
| When was DaShenLin Pharmaceutical founded? | DaShenLin Pharmaceutical was founded in 1999. |
| Where is DaShenLin Pharmaceutical headquartered? | DaShenLin Pharmaceutical is headquartered in China. |
| Is DaShenLin Pharmaceutical publicly listed? | Yes, DaShenLin Pharmaceutical is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical trades under 603233 ticker. |
| When did DaShenLin Pharmaceutical go public? | DaShenLin Pharmaceutical went public in 2017. |
| Who are competitors of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical main competitors include COSMOS Pharmaceutical, Sundrug, Fragua, Sugi Holdings, Nahdi Medical, Ebos Group, Clicks Group, Jointown Pharmaceutical, Kusuri No Aoki, Yifeng Pharmacy. |
| What is the current market cap of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's current market cap is $3B. |
| What is the current revenue of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months revenue is $4B. |
| What is the current revenue growth of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of DaShenLin Pharmaceutical? | Current revenue multiple of DaShenLin Pharmaceutical is 0.7x. |
| Is DaShenLin Pharmaceutical profitable? | Yes, DaShenLin Pharmaceutical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months EBITDA is $512M. |
| What is DaShenLin Pharmaceutical's EBITDA margin? | DaShenLin Pharmaceutical's last 12 months EBITDA margin is 12%. |
| What is the current EV/EBITDA multiple of DaShenLin Pharmaceutical? | Current EBITDA multiple of DaShenLin Pharmaceutical is 5.5x. |
| What is the current FCF of DaShenLin Pharmaceutical? | DaShenLin Pharmaceutical's last 12 months FCF is $491M. |
| What is DaShenLin Pharmaceutical's FCF margin? | DaShenLin Pharmaceutical's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of DaShenLin Pharmaceutical? | Current FCF multiple of DaShenLin Pharmaceutical is 5.8x. |
| How many companies DaShenLin Pharmaceutical has acquired to date? | DaShenLin Pharmaceutical hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies DaShenLin Pharmaceutical has invested to date? | As of May 2026, DaShenLin Pharmaceutical has invested in 2 companies. |
| What was the last DaShenLin Pharmaceutical investment? | On 8th November 2018 DaShenLin Pharmaceutical invested in LASO Biotech, participating in a $5M Angel round. |
| In what companies DaShenLin Pharmaceutical invested in? | DaShenLin Pharmaceutical invested in LASO Biotech and One Tree Pharmaceutical. |
See public comps similar to DaShenLin Pharmaceutical
Lists including DaShenLin Pharmaceutical
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
